The successful use of dicumarol in the prevention of intravascular thrombosis and subsequent embolism has led to the investigation of other coumarin compounds as therapeutic anticoagulants. No. 63 is such a compound. Like dicumarol, it induces hypoprothiombinemia and daily tests of piothrombin time are necessary as a guide to dosage. Our experience indicates that a less fluctuating and somewhat more consistent therapeutic hypoprothrombinemia can be established and maintained with anticoagulant No. 63 than with (licumarol. The potential disadvantage of the prolonged hypoprothrombinemia after administration is stopped is counterbalanced by the strong and relatively rapid antagonistic effect of vitamin K,. T HE first synthesis of 4-hydroxycoumarini anticoagulant, No. 63 (2-methyl-2methoxy-4-phenyl-5 -oxodihydropyrano-[3, 2-c] [1] benzopyran) was by Dr. Ikawa in the laboratory of Professor Karl Paul Link (fig. 1).' Battle, Capps, Orth and Meyer'2 have reported the results of experimental studies on animals and human beings with this anticoagulant and stated that prior observations on its action in animals were made by Scheel. The essential action of 4-hydroxycoumarin anticoagulant No. 63 is the induction of hypoprothrombiniemia as indicated by prolongation of the one stage prothrombin time, this action being similar to that of dicumarol (bishydroxycoumarini) to wshic(h it is chemically related. P'revious studies indicate that 4-hydroxycoumarin anticoagulant No. 63 is less soluble than dicumarol anlw is approximately two to three times more potent inl inducing hypoprothrombinemia oni the basis of milligrams per kilogram of body weight. Tche studies on animals have indicated that Shenl severe degrees of hypoprothrombinemia where induced and main taine(1 with 4-hyvdoxvcoumariii anticoagulant No. 63, mortality rates were lower From the Alavo Foun(lation and AMayo Clinic, Rochester, Milin. This paper is an .abridgment, with additions, of a thesis submitted by I)r. Hanson to the Faculty of the Graduate School of the Universitv of Minnesota in partial fulfillment of the requirements for the degree of Master of Science in Atedicine. 844 and beeding occurred less frequently than when comparable degrees of hypoprothromblinemia were induced and maintained by dicumarol. In their study of 15 patients who received 4-hydroxycoumarin anticoagulant No. (63, Battle and co-workers2 stated that an optimal effect could be established within 24 to 48 hours after anl original dose of 2 mg. peCI
prothiombinemia and daily tests of piothrombin time are necessary as a guide to dosage. Our experience indicates that a less fluctuating and somewhat more consistent therapeutic hypoprothrombinemia can be established and maintained with anticoagulant No. 63 than with (licumarol. The potential disadvantage of the prolonged hypoprothrombinemia after administration is stopped is counterbalanced by the strong and relatively rapid antagonistic effect of vitamin K,.
T HE first synthesis of 4-hydroxycoumarini anticoagulant, No. 63 (2-methyl-2- methoxy-4-phenyl-5 -oxodihydropyrano-[3, 2-c] [1] benzopyran) was by Dr. Ikawa in the laboratory of Professor Karl Paul Link ( fig. 1 ). ' Battle, Capps, Orth and Meyer'2 have reported the results of experimental studies on animals and human beings with this anticoagulant and stated that prior observations on its action in animals were made by Scheel. The essential action of 4-hydroxycoumarin anticoagulant No. 63 is the induction of hypoprothrombiniemia as indicated by prolongation of the one stage prothrombin time, this action being similar to that of dicumarol (bishydroxycoumarini) to wshic(h it is chemically related. P'revious studies indicate that 4-hydroxycoumarin anticoagulant No. 63 is less soluble than dicumarol anlw is approximately two to three times more potent inl inducing hypoprothrombinemia oni the basis of milligrams per kilogram of body weight. Tche studies on animals have indicated that Shenl severe degrees of hypoprothrombinemia where induced and main taine(1 with 4-hyvdoxvcoumariii anticoagulant No. 63, mortality rates were lower From the Alavo Foun(lation and AMayo Clinic, Rochester, Milin. This paper is an .abridgment, with additions, of a thesis submitted by I)r. Hanson to the Faculty of the Graduate School of the Universitv of Minnesota in partial fulfillment of the requirements for the degree of Master of Science in Atedicine. 844 and beeding occurred less frequently than when comparable degrees of hypoprothromblinemia were induced and maintained by dicumarol. In their study of 15 patients who received 4-hydroxycoumarin anticoagulant No. (63, Battle and co-workers2 stated that an optimal effect could be established within 24 to 48 hours after anl original dose of 2 mg. peCI Kg. of body weight and maintained by doses of 0.5 to 1.0 mg. per Kg. given at intervals of one to four days. It also appealed that the effect of 4-hydroxycoumarini aniticoagulanit No. ()3 was more sustained after administration of the drug was stopped than wvas the effect of dicumarol. Rotter and Meyer' stated that menadione sodium bisulfite was not effective in accelerating the return of the prothrombin time to normal after it had been lengthened by 4-hydroxycotumarini anticoagulant. No. 63, but that vitamin Ki in doses of 250 mg. was effective in this regard. emia induced and maintained by the 4-hydroxycoumarin compounds is considered to be that indicated by prothrombin times between 27 and 58 seconds.5 Prothrombin time tests were done at daily intervals with a few exceptions and more frequently on some of the patients who received vitamin K1. Anticoagulant No. 63 was administered in the form of compressed tablets, each containing 25 mg. of the drug, and the entire amount given on any particular day was given in a single dose.
Thirty-one patients, all of whom had either arteriosclerosis obliterans, thromboangiitis obliterans or chronic venous insufficiency of the extremities, received the drug for special stud-blood urea gave results within normal limits in all when treatment was started. The usual dosage schedule was as follows: 100 to 150 mg. were given on the first day and 25 to 50 mg. on the second day; subsequent daily doses of 25 to 30 mg. were given on those days when they were considered to be indicated. As has been noted iii experiences with dicumarol and ethyl biscoumacetate (Tromexan), responses of the prothrombin time to anticoagulant No. 63 varied considerably among different patients and could not be predicted in advance; hence in order to maintain the hypoprothrombinemia withimi the therapeutic range it was necessary to individualize the amount and frequency of 84athe daily doses for each patient on the basis of the response to the original and subsequent doses ( fig. 2 ). Usually, daily doses were given until the prothrombin time was greater than 35 seconds. Subsequently, if the prothrombin time was within the therapeutic range, doses were usually given only on those days when the prothrombin time was less than that of the previous day and were omitted on those days when it was greater than that of the previous day, particularly in relatively sensitive patients. In more resistant patients a satisfac-activity were followed daily after the last dose of anticoagulant No. 63 had been given until normal prothrombin times were noted. The duration of the hypoprothrombinemia after thelast dose of the anticoagulant was. five days in four patients, six days in four patients, seven days in five patients, nine days in four patients and 10 to 14 days in five patients. The av-erage duration for the entiregroup was eight days. These observations confirm previous studies both in animals and human beings that, after administration of the! drug is dis-
Varying responses of three different patients to anticoagulant No. 63; the prothrombin time of each returned to normal rapidly after administration of vitamin K1. tory hypoprothrombinemia usually could be maintained by a daily dose of 25 to 75 mg. with only occasional omissions and occasional increases of the dose.
The prothrombin time was in the therapeutic range in 24 hours after administration of the first dose of anticoagulant No. 63 in five of the 100 patients, in 48 hours in 80, in 72 hours in 11 and in 96 hours in four. Thus the usual response was a prothrombin time still below the therapeutic range at the end of 24 hours but within the therapeutic range at 48 hours.
The prothrombin times of 22 patients who were not given a preparation having vitamin K continued, the hypoprothrombinemia induced by anticoagulant No. 63 persists for a definitely longer period than that induced by dicumarol.
Among the 69 patients who received anticoagulant No. 63 for sustained therapy the duration of treatment was as follows: one to two weeks, 49 patients; two to three weeks, nine patients; three to four weeks, three patients; four to five weeks, three patients; five to six weeks, five patients. Excessive hypoprothrombinemia as indicated by prolongation of the prothrombin time to levels above those of the therapeutic range developed in 22 patients, usually on the fourth or fifth day of treatment.
The prothrombin time fell below the therapeutic range during treatment in only four patients.
Four patients died during treatment with anticoagulant No. 63. The cause of death in all -was myocardial infarction of severe degree, 'which was present when treatment was begun. 'The myocardial infarction of three of these patients was recent and that of one patient was .old. At necropsy no evidence of bleeding was -found in three but in the fourth there was 300 .cc. of bloody fluid in the pericardial sac. This patient had an extensive degenerating myo-*cardial infarct and it is unlikely that the bleeding contributed to the patient's death. No evidence of intracardiac or peripheral vascular thrombosis was found at necropsy in any of -the four patients who died.
Clinical evidence of minor bleeding was found during treatment in only four of the .entire series of patients who received anticoagulant No. 63, as follows: ecchymosis in the skin .of an ischemic extremity in two, hemoptysis -without objective evidence of pulmonary lesion -in one, epistaxis and slight vaginal bleeding in one who had had recent total abdominal hysterectomy. In two of these four patients -the prothrombin time was within the therapeutic range and in the other two it was definitely above the therapeutic range when bleeding occurred. Major bleeding from the vagina developed in one patient after six days of treatment. This patient had undergone vaginal hysterectomy two weeks previously, and anticoagulant therapy was employed because of thrombosis of the external jugular vein. The bleeding developed while the prothrombin time was within the therapeutic range and stopped when the hypoprothrombinemia was corrected. One patient had urticaria shortly after the first dose of anticoagulant No. 63 had been given; however, this subsided and did not reappear despite the fact that anticoagulant therapy was continued without interruption.
No other untoward effects were noted in any of the 100 patients who received anticoagulant No. 63. No clinical evidence of fresh thrombosis or embolism was noted in any of the patients during the period of treatment with anticoagulant No. 63. Anticoagulant No. 63 induced adequate hypoprothrombinemia within 48 hours after the first dose had been given, and there was no difficulty in maintaining the hypoprothrombinemia within the therapeutic range with this anticoagulant in five patients who had been found to be very resistant to dicumarol. In this group of patients the use of dicumarol in fairly large doses had failed to prolong the prothrombin time into the therapeutic range.
THE ANTAGONISTIC EFFECTS OF VITAMIN K1
AND MENADIONE SODIUM BI9ULFITE Because of the observation that the hypoprothrombinemia induced by anticoagulant No. 63 tends to persist for a number of days after the last dose of the drug has been given, some means for reversing this hypoprothrombinemia as rapidly as possible seemed highly desirable. For this purpose studies were made of the antagonistic effects of menadione sodium bisulfite and vitamin K1-9 The following studies were made on each of 10 patients. First, as a control study, therapeutic hypoprothrombinemia was induced by anticoagulant No. 63. The administration of the drug was stopped and the period required for the prothrombin time to return to normal was determined. After the prothrombin time had been normal on two consecutive days, identical doses of anticoagulant No. 63 were administered on days corresponding to the days of administration in the control study. After the last dose had been given, and during the period of induced therapeutic hypoprothrombinemia, 72 mg. of menadione sodium bisulfite was given intravenously and the period required for the prothrombin time to return to normal was determined. Anticoagulant No. 63 was administered a third time in doses identical to those in the control study and on corresponding days. Then 500 mg. of vitamin K1 was given orally on the day corresponding to the day that menadione sodium bisulfite had been given during the previous period of study and the time required for the prothrombin time to return to normal was determined. In different subjects, different days after administration of the first dose of anticoagulant No. 63 were selected for administration of the antagonist, control study. This method of study is illustrated in figure 3 .
The results obtained are shown in table 1. Menadione sodium bisulfite decreased the recovery period, over that of the control, by zero to four days with an average of one and two-tenths days. It also decreased the duration of the period which elapsed before the prothrombin time fell to the lower limit of the therapeutic range (27 seconds or below) by an average of one and one-half days. Vitamin K1 reduced the recovery period to one day for all except one patient who required three days; thus decreasing the recovery period, over that of the control, by an average of four and seventenths days. Vitamin K1 caused the prothrombin time to fall to the lower limit of the therapeutic range or below within eight hours after administration in nine cases, and within 24 hours in all cases.
The molecular weight of vitamin K, (2-methyl-3-phytyl-1,4-naphthoquinone) is 1.6 times that of menadione sodium bisulfite (2-methyl-1,4-naphthoquinone-3-sodium sulfonate); hence, from the standpoint of molecular weights the doses used (72 mg. of menadione sodium bisulfite and 500 mg. of vitamin K1) are not comparable ( fig. 1 ). These doses were selected because they have previously been considered the maximal effective doses for each of these compounds when used to counteract the hypoprothrombiniemia induced by dicumarol. Since the dose of vitamin K1 was 500 mg. and it was giveni orally, 500 mg. of menadione bisulfite was administered orally to each of three patients who had hypopro-patients who required varying amounts of the drug to induce and maintain a therapeutic hypoprothrombiriemial (total amount varying from 150 to 850 mg.) anll to patients with the prothrombin times at various levels (32 to 102 seconds). In four patients the prothrombin time was significantly prolonged beyond thrombinemia induced by anticoagulant No. 63. Four days were required for the prothrombin time to return to normal in two of these patients and seven days in the third. In table 2 it is shown that in paired patients with comparable degrees of hypoprothrombinemia given identical doses in milligrams of the two antagonists by the same route of administration, the effect of vitamin K, was considerably more rapid than that of menadionie bisulfite. In order to test further the effectiveness of vitamin K1 in eorrecting a sustained hypoprothrombinemia induced and maintained by anticoagulant No. 63, 26 of the patients who had been receiving this drug for varyinig periods were given e500 mg. of vitamin K1 orally, when it became desirable to terminate the anticoagulant therapy. It was felt that the total amount of the drug which the patient had received anid the duration of the hypoprothrombinemia, as well as the length of the prothrombin time, at the time when vitamin K1 was giveni, might in'xienice the response. Hence, vitamin K1 was giveen atldifferent times from 3 to 14 days (figs. 2 and 4) after treatment with arkticoagulanit No. 63 lhas l)eeni initiated, to 1 3 4 5 6 7 8 9 10 11 13 14 l's 16 Days Fi(;. 4. Relatively constaiit hvpoprl)iIothroml)iiiemia, Within the therapeutic rainge, maintaineid for 14 days by insfrequent doses of anticoagulant No. 63 ands(1 then terminat edi rapidly after .a(lminiistratiols of vitamin 1K1. the upper limit of the therapeutic range when vitamin 1K1 was given. In three patients this excessive prolongation of the prothrombin time occurred after the usual therapeutic doses of anticoagulant No. (63, and in one the prothrombin time was deliberately forced beyond the therapeutic range by large doses of anticoagiilavit No. 63. 46 31 26 A summary of the results observed in this series of 26 patients is shown in table 3. Eight hours after the administration of vitamin K1, the prothrombin time had dropped significantly in all but two patients. It was at or below the lower limit of the therapeutic range (27 seconds or less, corresponding to 30 per cent or more Prothrombin time in seconds patient failed to show a significant reduction in the prothrombin time 24 hours following the administration of vitamin K1, and a rebound phenomenon was noted in another patient. 20  18  21  20  24  19  20  24  25  21  20  22  21  22  21  26   19  21  20  22  29  21  28  20  18  21  20  18  19  20  20  19  18  22  23  20  19 20 20 21 20 20 * Poor response to vitamin K,. patients had prothrombin times of 23 seconds or less 24 hours after administration of vitamin KI.
Vitamin K1 was administered intravenously to four patients who had therapeutic hypoprothrombinemia which had been induced and maintained by anticoagulant No. 63. It was prepared for intravenous administration by dissolving 500 mg. in 10 cc. of absolute alcohol and adding this solution to 500 cc. of sterile 5 per cent solution of glucose. The resulting liquid was an emulsion, and the amount which was administered is approximate since q 7( 4 6( nine patients, there was a reduction in the prothrombin time 24 hours following the administration of menadione sodium bisulfite, and a return to within the therapeutic range in six patients, but in none did the prothrombin time fall to less than 37 seconds. Forty-eight hours after the administration of menadione sodium bisulfite, the prothrombin time was found to have increased again in four of the nine patients, despite the fact that anticoagulant No. 63 was not administered during this period.
Refractoriness was noted after 500 mg. of vitamin K1 had been administered to two pa-18 0 Z 4 6 8 10 12 14 16 Days FIG. 5. Left: Failure of reinduction of hypoprothrombinemia by the same dose of anticoagulant No. 63 administered nine days after 500 mg. of vitamin K1 was given orally. Right: Successful but delayed reinduction of hypoprothrombinemia after vitamin K1 had been given by increasing the dose of anticoagulant No. 63. some of the emulsified drug adheres to the flask and tubing. The results obtained by the intravenous administration of vitamin K1 were much the same as those observed for patients who received vitamin K1 orally; however, there appeared to be a slightly more consistent and greater fall in the prothrombin time at the end of four hours when vitamin K1 was administered intravenously than when it was given orally.
Nine patients with hypoprothrombinemia resulting from therapy with anticoagulant No. 63, who had prothrombin times prolonged beyond the therapeutic range (considerably longer than 58 seconds), were given 72 mg. of menadionie sodium bisulfite intravenously. The results are shown in table 5. In this series of tients v ho had been treated with anticoagulant No 63. After their prothrombin times had returned to normal, they were given doses of the anticoagulant identical with those which had induced hypopronhrombinemia previously These doses had no effect whatsoever on the patients' prothrombin times. This refractoriness to the usual induction doses of anticoagulant No. 63 was noted as long as 12 and 14 days after administration of vitamin K,. Subsequently each of four patients with hypoprothrombinemia induced by anticoagulant No. 63 was given vitamin K1 in doses of 50 to 500 mg. and, beginning 8 to 24 hours later, reinduction of hypoprothrombinemia was attempted. This was accomplished in two to four days in all four patients by giving two or three 5 ). Once reinduction of therapeutic hypoprothrombinemia was effected, the maintenance dose of anticoagulant No. 63 remained the same as that prior to the administration of -vitamin K1.
No untoward symptoms or toxic manifestations were itoted after oral or intravenous administration of vitamin K1. The same was true for menadioiie sodium bisulfite given intravenously and meniadionie bisulfite given orallyr.
SUMNIMIARY
Our studies indicate that 4-hydroxycoumanini anticoagulant No. 63 is a satisfactory anticoagulant for cliniical use. The action of this drug is similar to dicumarol and for this reason contraindicationis to, and cautions regardiiig, the use of anticoagulant No. 63 are the same as those for dicumaxol. As with dicumarol, there are great variations in the response of different patients to fixed doses of anticoagulant No. 63 and the drug should not l)e used unless its effects can be followed by laily tests of the prothrombin time.
The doses of dr(g for induction of therapeutic hypoprothrombinemia are roughly onethird to one-half the amounts in milligrams of the doses of dicumarol used for the same purposes. Dosages required to maintain hypoprot hrombinemia within the therapeutic range are also one-third to one-half those of dicumarol and may be given less frequently. Anticoagulant No. 63 appears to be somewhat more dependable than dicumarol for the induction of therapeutic hypoprothrombinemia although whether or not it acts more rapidly is questionable. Some patients who have been highly resistant to dicumarol have responded satisfactorily to anticoagulant No. 63. In our experience, maintenance of therapeutic hypoprothrombinemia without marked fluctuations of the prothrombin time seems to be accomplished a little more easily when anticoagulant No. 63 is used than when dicumarol is used. Following cessation of administration of anti-(oagulant No. 63, hypoprothrombinemia persists for a longer time (average eight days) than after cessation of the administration of dicumarol. i\Ienadione sodium bisulfite in doses of 72 mg. appears to be effective in some instances in reducing to the therapeutic range a prothrombin time which is excessively prolonged by anticoagulant No. 63. This is especially true of patients who are hypersensitive to this anticoagulant. However, meniadione sodium bisulfite has only a slight effect in accelerating the return of the prothrombini time from the therapeutic range to normal after it has been prolonged by anticoagulant No. 63. Vitamin K1 in 500 mg. doses, given either orally or intravenously, is effective in almost all cases in greatly a((elerating the retuni of the pro-thrombini time to normal after it has been prolonged by anticoagulant No. 63. The return to normal or niear normal levels almost always occurs within twvenity-fouir hours. Following the use of vitamini K1 patients are somewhat refractory to aniti(oaguilatit 'No. 63. The potential antagonistic actioni of vitamin IEl counterbalances the disadvantage of the prolonged duration of hypoprotlirombiniemia after administration of aiiticoagulant No. 63 is discontinued. Although the number of patients studied is too small to permit us to formulate definite conclusions, it is probable that if the degrees of therapeutic hypoprothrombinemia induced and maintained by anticoagulant No. 63 are comparable to those induced and maintained by dicumarol, anticoagulant No. 63 will be as effective in preventing thrombosis as dicumarol, and its use will be attended with approximately the same risk of bleediiig.
